PDE10

BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers

Retrieved on: 
Monday, March 25, 2024
Professional Services, Health, Finance, Clinical Trials, Research, Science, Pharmaceutical, PDE10, Phases of clinical research, Ulcerative colitis, Brain, IL6, Disease, Tumor necrosis factor, Central nervous system, IL8, Benevolence, Patient, CNS, CGMP, UC, Camp, Șaeș, Trial of the century, BAI, Cytokine, Drug development, Safety, Inflammatory bowel disease, Euronext Amsterdam, Steroid, JAK, Pharmaceutical industry

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.
  • As a result, BenevolentAI’s scientists designed BEN-8744 to be not only a potent PDE10 inhibitor, but also a peripherally-restricted molecule, i.e.
  • The Phase Ia study results support this profile, showing no evidence of CNS-associated adverse events at any dose level.
  • It is anticipated that the full results from this study will be presented in a peer-reviewed forum at a later date.

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, PDE10, Ulcerative colitis, Neurology, AstraZeneca, Atopic dermatitis, ALS, Glioblastoma, Drug discovery, Benevolence, Patient, GBM, Cash, UC, Chairperson, Research, Merck, IND, SBP, BAI, Retinoic acid receptor alpha, Safety, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.
  • Dr. Joerg Moeller, Chief Executive Officer (CEO) of BenevolentAI, said:
    "I am delighted to present my inaugural set of financial results as the CEO of BenevolentAI.
  • I look forward to working closely with them, and our partners, to make a lasting impact on the lives of patients worldwide."
  • Cash, cash equivalents and short-term deposits position of £72.9 million at 31 December 2023 (31 December 2022: £130.2 million), compared with £84.3 million at 30 June 2023.

BenevolentAI: Shareholder Letter December 2023

Retrieved on: 
Thursday, December 28, 2023
Technology, Research, Finance, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Knowledge, Biology, Drug, Conference, Culture, Merck Group, Drug discovery, Medicine, ALS, AstraZeneca, Business, Data, UC, Retinoic acid receptor alpha, PDE10, AI, Business development, ID, Glioblastoma, Food, SAD, Merck, GBM, Growth, Benchmarking, Patient, Safety, Benevolence, Acceleration, Heart failure, Neurology, Ulcerative colitis, Pharmaceutical industry

Despite 2023 being a challenging year and a transition period for BenevolentAI, we have made significant progress in executing our strategic plan.

Key Points: 
  • Despite 2023 being a challenging year and a transition period for BenevolentAI, we have made significant progress in executing our strategic plan.
  • We were pleased with the signing of the new strategic collaboration with Merck KGaA in September.
  • We also introduced a new state-of-the-art target prediction methodology, which continues to enhance our previous target prediction fleet and target explanations.
  • As announced in our interim results announcement in September, we expect that headcount will be around 260 employees at the end of 2023.

BenevolentAI: Interim Results for the Six Months Ended 30 June 2023

Retrieved on: 
Thursday, September 21, 2023
Technology, Research, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Knowledge, Acceleration, Serum response factor, Katherine, Interim, Chronic kidney disease, Normalization, ALS, GBM, Retinoic acid receptor alpha, Sustainability Accounting Standards Board, PDE10, Sutro Biopharma, Dragon (magazine), Glioblastoma, Benevolence, AstraZeneca, Ulcerative colitis, BAI, Nouvelle AI, Euronext, UC, SLS, Euronext Amsterdam, Drug discovery, Heart failure, Merck, AI, IPF, CKD, Neurology, Idiopathic pulmonary fibrosis, Success, Conference, Pharmaceutical industry, Management, Sales, Medical device, Cryptocurrency, IND

BenevolentAI (Euronext Amsterdam: BAI) (“BenevolentAI” or the “Company” or the “Group”), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2023.

Key Points: 
  • BenevolentAI (Euronext Amsterdam: BAI) (“BenevolentAI” or the “Company” or the “Group”), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2023.
  • We committed in May to right-sizing the business which has resulted in an extension of our cash runway to at least mid-2025.
  • In particular, I want to thank Joanna for her commitment over the last five years to build the business into what it is today.
  • Operating cash flow before changes in working capital reduced by 22% from £48.4 million (H1 2022) to £37.9 million.

BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis

Retrieved on: 
Thursday, August 31, 2023
Research, Technology, Biotechnology, General Health, Pharmaceutical, Health, Data Management, Science, Artificial Intelligence, Other Science, PDE10, BAI, UC, Ulcerative colitis, Disease, Euronext Amsterdam, Pharmaceutical industry, Medical device

The topline data readout from this study is expected in Q1 2024.

Key Points: 
  • The topline data readout from this study is expected in Q1 2024.
  • Dr. Anne Phelan, Chief Scientific Officer of BenevolentAI, said: “UC is a disease with significant unmet patient needs, as rates of sustained remission remain disappointingly low.
  • Initiation of this Phase I study marks a significant milestone in treating this complex disease and serves as the leading asset in our clinical development portfolio.
  • BEN-8744 demonstrates the capacity of our technology platform to uncover novel avenues in the treatment of disease.”

BenevolentAI Unveils Strategic Plan to Position the Company for a New Era in AI

Retrieved on: 
Thursday, May 25, 2023
Health, Technology, Health Technology, Software, Artificial Intelligence, Biotechnology, PDE10, ALS, Glioblastoma, Science, BAI, SVP Worldwide, Ulcerative colitis, Amyotrophy, Euronext Amsterdam, Drug discovery, Artificial intelligence, CFO, Knowledge, AI, Guinea pig maximisation test, SVP, News, Procedure, Medical device, Video game, Airline, Management, Fine chemical, Pharmaceutical industry, Fibrosis

Simultaneously, the Company is optimising its portfolio to focus on its most advanced and promising pipeline assets.

Key Points: 
  • Simultaneously, the Company is optimising its portfolio to focus on its most advanced and promising pipeline assets.
  • Maximises the impact of BenevolentAI’s innovative technology platform for commercial deployment through new revenue-generating products, collaborations and partnerships.
  • Prioritises the Company’s most advanced and high-potential clinical and pre-clinical assets, progressing them to their value inflection points.
  • In summary, this strategic review and reorganisation positions BenevolentAI to maximise value creation for stakeholders.

EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury

Retrieved on: 
Wednesday, February 8, 2023
Autism, PDE10, CNS, Anesthesiology, Critical care, Head injury, Government, Quality of life, TBI, Disability, Hospital, Therapy, United States Department of Defense, NMDAR, Brain, University, Patient, Tourette syndrome, ASD, Nerve, NMDA, Hospital of the University of Pennsylvania, Death, Toxicity, Department of Defense Serum Repository, Neuropsychiatric Disease and Treatment, Research, CHOP, Medical device, Pharmaceutical industry, Fine chemical, Defense

A key scientific focus of EuMentis is to advance novel fast-off NMDAR antagonists to block signaling of over-active glutamate receptors in order to restore glutamate balance across diseases and indications, including TBI.

Key Points: 
  • A key scientific focus of EuMentis is to advance novel fast-off NMDAR antagonists to block signaling of over-active glutamate receptors in order to restore glutamate balance across diseases and indications, including TBI.
  • Once the preclinical study is completed, EuMentis plans to advance the selected lead candidate into a Phase I clinical trial in 2024.
  • To date, EuMentis has received over $11 million in funding from private and government sources to support research and development of its broad pipeline of novel CNS-based therapeutics.
  • “Currently there are no approved therapeutics for traumatic brain injury, which impact hundreds of thousands of Americans annually and leads to significant disability and death.

BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis

Retrieved on: 
Wednesday, December 21, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, BAI, Disease, UC, MHRA, CTA, Ulcerative colitis, Euronext, PDE10, Drug discovery, Medicines and Healthcare products Regulatory Agency, Pharmaceutical industry

BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug discovery company, announces it has submitted a Clinical Trial Application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of ulcerative colitis (UC).

Key Points: 
  • BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug discovery company, announces it has submitted a Clinical Trial Application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of ulcerative colitis (UC).
  • Subject to obtaining MHRA approval on the CTA, BenevolentAI plans to initiate a Phase I clinical trial of BEN-8744, anticipated to commence in the first half of 2023.
  • We believe BEN-8744 has the potential to be a novel treatment for UC: a complex multifactorial disease that remains underserved by current standard-of-care therapies.
  • After rapidly delivering this drug candidate within just two years of target validation, we look forward to commencing first-in-human studies next year.”

MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

Retrieved on: 
Friday, April 8, 2022
Brain, Private Securities Litigation Reform Act, Risk, Amyotrophic lateral sclerosis, Experiment, Multiple sclerosis, University of California, San Diego Performance-Based Skills Assessment, MIF, DCM, Form 10-K, Lists of diseases, Glioblastoma, NASDAQ, Substance dependence, Idiopathic pulmonary fibrosis, Code, Form 8-K, Alcoholism, NIAAA, Neurodegeneration, Patient, Tokyo Stock Exchange, Annual report, ALS, Crave, Camp, MPH, Alcoholism: Clinical and Experimental Research, Failure, PDE10, U.S. Securities and Exchange Commission, Psychiatry, PDE4, MD, Disorder, IPF, NASH, Security (finance), AUD, MS, CIPN, DDA, Intellectual property, Nucleus accumbens, GLOBE, Drinking, Fatty liver disease, FDA, Acute respiratory distress syndrome, Nasdaq, University, Disease, Chemotherapy-induced peripheral neuropathy, Pharmaceutical industry, Beer, Doctor of Philosophy

Eligible participants were randomized to MN-166 (ibudilast) or matched placebo and completed daily diary assessments (DDAs) during the two-week period.

Key Points: 
  • Eligible participants were randomized to MN-166 (ibudilast) or matched placebo and completed daily diary assessments (DDAs) during the two-week period.
  • Multilevel models compared the effects of MN-166 (ibudilast) and placebo on subjective alcohol response.
  • We are pleased that the results of this secondary analysis are consistent with the findings from the primary analysis.
  • Alcohol use disorder (AUD) is a prevalent and disabling psychiatric disorder with limited treatment options.